title: IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis.
authors.forename: L H D
authors.initials: LH
authors.lastname: van Tuyl
authors.forename: W F
authors.initials: WF
authors.lastname: Lems
authors.forename: P J S M
authors.initials: PJ
authors.lastname: Kerstens
authors.forename: A E
authors.initials: AE
authors.lastname: Voskuyl
authors.forename: B A C
authors.initials: BA
authors.lastname: Dijkmans
authors.forename: M
authors.initials: M
authors.lastname: Boers
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology*; D012217:Rheumatoid Factor / Q000097:blood
chemical_list: D018501:Antirheumatic Agents; D001323:Autoantibodies; D015415:Biomarkers; D007075:Immunoglobulin M; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D012217:Rheumatoid Factor